title: Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
abstract: Detection of minimal residual disease predicts adverse outcome in patients with acute myeloid leukemia. Currently, minimal residual disease may be detected by RQ-PCR or flow cytometry, both of which have practical and diagnostic limitations. Here, we describe a next-generation sequencing assay for minimal residual disease detection in NPM1-mutated acute myeloid leukemia, which encompasses ∼60% of patients with normal karyotype acute myeloid leukemia. Exon 12 of NPM1 was PCR amplified using sequencing adaptor-linked primers and deep sequenced to enable detection of low-prevalence, acute myeloid leukemia-specific activating mutations. We benchmarked our results against flow cytometry, the standard of care for acute myeloid leukemia minimal residual disease diagnosis at our institution. The performance of both approaches was evaluated using defined dilutions of an NPM1 mutation-positive cell line and longitudinal clinical samples from acute myeloid leukemia patients. Using defined control material, we found this assay sensitive to approximately 0.001% mutant cells, outperforming flow cytometry by an order of magnitude. Next-generation sequencing was precise and semiquantitative over four orders of magnitude. In 22 longitudinal samples from six acute myeloid leukemia patients, next-generation sequencing detected minimal residual disease in all samples deemed negative by flow cytometry. Further, in one-third of patients, sequencing detected alternate NPM1 mutations in addition to the patient's index mutation, consistent with tumor heterogeneity. Next-generation sequencing provides information without prior knowledge of NPM1 mutation subtype or validation of allele-specific probes as required for RQ-PCR assays, and without generation and interpretation of complex multidimensional flow cytometry data. This approach may complement current technologies to enhance patient-specific clinical decision-making.
authors.affiliation: 1] Departments of Laboratory Medicine, University of Washington, UW Hematopathology Laboratory at SCCA, Seattle, WA, USA [2] Genome Sciences, University of Washington, Seattle, WA, USA.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Salipante
authors.affiliation: Departments of Laboratory Medicine, University of Washington, UW Hematopathology Laboratory at SCCA, Seattle, WA, USA.
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Fromm
authors.affiliation: Genome Sciences, University of Washington, Seattle, WA, USA.
authors.forename: Jay
authors.initials: J
authors.lastname: Shendure
authors.affiliation: Departments of Laboratory Medicine, University of Washington, UW Hematopathology Laboratory at SCCA, Seattle, WA, USA.
authors.forename: Brent L
authors.initials: BL
authors.lastname: Wood
authors.affiliation: Departments of Laboratory Medicine, University of Washington, UW Hematopathology Laboratory at SCCA, Seattle, WA, USA.
authors.forename: David
authors.initials: D
authors.lastname: Wu
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D004252:DNA Mutational Analysis / Q000379:methods*; D005091:Exons; D005434:Flow Cytometry; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D009154:Mutation; D018365:Neoplasm, Residual; D009687:Nuclear Proteins / Q000235:genetics*; D000090243:Nucleophosmin; D010865:Pilot Projects; D016133:Polymerase Chain Reaction; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D000090243:Nucleophosmin
references.citation: Clin Cancer Res. 2014 Sep 1;20(17):4540-8
references.pmid: 24970842
references.citation: Curr Opin Oncol. 2010 Nov;22(6):656-63
references.pmid: 20805746
references.citation: ISME J. 2012 Aug;6(8):1621-4
references.pmid: 22402401
references.citation: Blood. 2012 Dec 20;120(26):5173-80
references.pmid: 23074282
references.citation: Blood. 2009 Sep 10;114(11):2220-31
references.pmid: 19587375
references.citation: Blood. 2004 Nov 15;104(10):3078-85
references.pmid: 15284114
references.citation: N Engl J Med. 2013 May 30;368(22):2059-74
references.pmid: 23634996
references.citation: Blood. 2012 Jan 12;119(2):332-41
references.pmid: 22039260
references.citation: Semin Oncol. 2008 Aug;35(4):388-400
references.pmid: 18692689
references.citation: Genome Biol. 2011 Dec 20;12(12):R124
references.pmid: 22185227
references.citation: Hematology Am Soc Hematol Educ Program. 2012;2012:35-42
references.pmid: 23233558
references.citation: Blood. 2013 Jul 4;122(1):100-8
references.pmid: 23704090
references.citation: Blood. 2013 Sep 5;122(10):1813-21
references.pmid: 23847197
references.citation: Arch Pathol Lab Med. 2006 May;130(5):680-90
references.pmid: 16683886
references.citation: Leukemia. 2005 Oct;19(10):1760-7
references.pmid: 16079892
references.citation: Bioinformatics. 2010 Mar 1;26(5):589-95
references.pmid: 20080505
references.citation: Blood. 2013 Jul 4;122(1):83-92
references.pmid: 23656730
references.citation: Cell. 2012 Jul 20;150(2):264-78
references.pmid: 22817890
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14275-80
references.pmid: 14614138
references.citation: J Clin Oncol. 2013 Nov 1;31(31):3898-905
references.pmid: 24062393
references.citation: J Mol Diagn. 2014 Jan;16(1):56-67
references.pmid: 24189654
references.citation: J Clin Oncol. 2011 Mar 20;29(9):1190-7
references.pmid: 21282535
references.citation: BMC Bioinformatics. 2012 Feb 14;13:31
references.pmid: 22333067
references.citation: Blood. 2005 Oct 15;106(8):2854-61
references.pmid: 15994285
references.citation: Cytometry B Clin Cytom. 2004 Nov;62(1):25-38
references.pmid: 15468339
references.citation: Sci Transl Med. 2012 May 16;4(134):134ra63
references.pmid: 22593176
references.citation: N Engl J Med. 2009 Sep 10;361(11):1058-66
references.pmid: 19657110
references.citation: Methods Mol Biol. 2013;999:123-36
references.pmid: 23666694
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2709-16
references.pmid: 21555683
references.citation: N Engl J Med. 2005 Jan 20;352(3):254-66
references.pmid: 15659725
references.citation: Exp Hematol. 2009 Jan;37(1):135-42
references.pmid: 19100523
references.citation: Leukemia. 2013 Sep;27(9):1820-5
references.pmid: 23702683
references.citation: Clin Lymphoma Myeloma. 2009;9 Suppl 3:S281-5
references.pmid: 19778853
references.citation: Genes Chromosomes Cancer. 2012 Jul;51(7):689-95
references.pmid: 22454318
references.citation: Genome Res. 2012 Mar;22(3):568-76
references.pmid: 22300766
references.citation: J Mol Diagn. 2010 Sep;12(5):629-35
references.pmid: 20616361
references.citation: Blood. 2011 Jan 27;117(4):1109-20
references.pmid: 21030560
references.citation: Nature. 2012 Jan 11;481(7382):506-10
references.pmid: 22237025
references.citation: Genome Res. 2013 May;23(5):843-54
references.pmid: 23382536